

Jacinta A Holmes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6137460/publications.pdf>

Version: 2024-02-01

32
papers

620
citations

567281

15
h-index

610901

24
g-index

32
all docs

32
docs citations

32
times ranked

1282
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis B and Hepatitis C Virus Infection Promote Liver Fibrogenesis through a TGF- β 2-Induced OCT4/Nanog Pathway. <i>Journal of Immunology</i> , 2022, 208, 672-684.	0.8	12
2	Editorial: hepatocellular carcinoma risk prediction models following DAA-mediated SVR—more evidence needed. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 135-136.	3.7	0
3	Hematemesis, Abnormal Liver Function, and Polymicrobial Bacteremia: A Rare Complication of a Common Cancer. <i>Gastroenterology</i> , 2021, 160, 1031-1033.	1.3	0
4	Fatty Acids Activate the Transcriptional Coactivator YAP1 to Promote Liver Fibrosis via p38 Mitogen-Activated Protein Kinase. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 1297-1310.	4.5	28
5	<i>Helicobacter pylori</i> antimicrobial resistance in Melbourne, Australia. Time to review therapeutic guidelines?. <i>Internal Medicine Journal</i> , 2021, 51, 1919-1926.	0.8	6
6	Author reply. <i>Internal Medicine Journal</i> , 2021, 51, 2164-2164.	0.8	0
7	New approaches in viraemic organ transplantation and antiviral therapies. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 78-79.	17.8	3
8	Shortening treatment with direct-acting antivirals in HCV-positive organ transplantation. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 626-627.	8.1	2
9	Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. <i>Journal of Hepatology</i> , 2020, 73, 62-71.	3.7	60
10	Non-invasive fibrosis algorithms are clinically useful for excluding cirrhosis in prisoners living with hepatitis C. <i>PLoS ONE</i> , 2020, 15, e0242101.	2.5	6
11	COVID-19 induced liver function abnormality associates with age. <i>Aging</i> , 2020, 12, 13895-13904.	3.1	13
12	Title is missing!. , 2020, 15, e0242101.		0
13	Title is missing!. , 2020, 15, e0242101.		0
14	Title is missing!. , 2020, 15, e0242101.		0
15	Title is missing!. , 2020, 15, e0242101.		0
16	Microrna-130a Downregulates HCV Replication through an atg5-Dependent Autophagy Pathway. <i>Cells</i> , 2019, 8, 338.	4.1	19
17	Direct-acting antiviral treatment for hepatitis C. <i>Lancet</i> , The, 2019, 393, 1392-1394.	13.7	47
18	A Long Noncoding RNA Regulates Hepatitis C Virus Infection Through Interferon Alpha-Inducible Protein 6. <i>Hepatology</i> , 2019, 69, 1004-1019.	7.3	45

#	ARTICLE	IF	CITATIONS
19	Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infection. <i>Journal of Viral Hepatitis</i> , 2019, 26, 362-372.	2.0	21
20	MicroRNA 130a Regulates both Hepatitis C Virus and Hepatitis B Virus Replication through a Central Metabolic Pathway. <i>Journal of Virology</i> , 2018, 92, .	3.4	32
21	Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis. <i>Hepatology</i> , 2018, 68, 1125-1139.	7.3	74
22	IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR. <i>Journal of Viral Hepatitis</i> , 2018, 25, 465-472.	2.0	15
23	Hepatitis B reactivation during or after direct acting antiviral therapy – implication for susceptible individuals. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 651-672.	2.4	44
24	Lupus-Like Immune Complex-Mediated Glomerulonephritis in Patients With Hepatitis C Virus Infection Treated With Oral, Interferon-Free, Direct-Acting Antiviral Therapy. <i>Kidney International Reports</i> , 2016, 1, 135-143.	0.8	26
25	IQGAP2 is a novel interferon-alpha antiviral effector gene acting non-conventionally through the NF- κ B pathway. <i>Journal of Hepatology</i> , 2016, 65, 972-979.	3.7	16
26	Exposure to human immunodeficiency virus/hepatitis C virus in hepatic and stellate cell lines reveals cooperative profibrotic transcriptional activation between viruses and cell types. <i>Hepatology</i> , 2016, 64, 1951-1968.	7.3	36
27	HCV compartmentalization in HCC: driver, passenger or both?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 254-256.	17.8	5
28	Reply. <i>Hepatology</i> , 2015, 61, 409-409.	7.3	0
29	The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 296-306.	3.7	11
30	ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. <i>Hepatology</i> , 2014, 59, 2152-2160.	7.3	25
31	IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-1. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 861-866.	2.8	41
32	Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?. <i>Journal of Viral Hepatitis</i> , 2012, 19, 677-684.	2.0	33